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In recent years, there has been a remarkable increase 
in the number of patients who benefit from cardiovascular 
implantable devices. On the other hand, magnetic 
resonance imaging (MRI) compared with other imaging 
techniques undoubtedly has many advantages regarding 
its discrimination ability without radiation exposure. The 
risks of scanning device patients that have non “MR 
Safe” or “MRConditional” devices (Table 1), due to field 
effects, are well known as are the risk mitigation 
strategies. 
 
Hazards and safety concerns 
 
There are three distinct mechanisms associated with 
MRI that can give rise to potential risks related to 
cardiovascular devices: (1) the static magnetic field, (2) 
radiofrequency (RF) energy, (3) gradient magnetic fields 
or any combination of them. Static main magnetic field 
exposes ferromagnetic components to mechanical forces 
and torque and causes unpredictable magnetic sensor 
activation, reed switch closure and electrocardiograms 
distortions on electronic implantable pulse generators 
(IPGs), implantable cardioverter defibrillators (ICDs) and 
cardiac resynchronization therapy (CRT) devices. 
Modulated RF field interacts with pacemaker devices and 
leads causing heating of cardiac tissue adjacent to 
electrodes, reset and sensing problems of the device. 
ICDs can falsely detect RF field as ventricular 
tachycardia (VT) and start the sequence of defibrillation. 
Gradient magnetic field can induce currents in electrically 
conductive wires and leads that could cause over-/under-
sensing and induce arrhythmias. Combined field effects 
can cause alteration of device function, vibrations, 
electronic reset and device or lead damage. Electrical 
reset is a safety emergency mode that limits pacemaker 
functionality to minimal in case of battery depletion or 
dip due to MR field interference. Factory default settings 
and usually a VVI mode are set while ICD therapies are 
deactivated. Because ICD’s parts, such as capacitors and 
batteries, are much larger than those of pacemakers and 
the technology used is more complicated they tend to 
pose greater conflicts, electromagnetic and mechanical 
forces (10 times higher than pacemaker), under MRI 
conditions. Generally pacemakers are switched to 
asynchronous magnet or interference mode and ICD 
therapy is switched off after MR field exposure. On the 
other hand, pacemaker leads left in place after device 
removal are “antennas” causing heating even if isolated 
by silicon cup and in some cases heat generated is higher 
than normally connected leads. Temporary epicardial 
pacing stainless steel leads after cardiac surgery seem to 
post no threads during non cardiac MRI.39, 40 Another 
aspect that should be considered is image artifacts due to 
implanted devices near the imaging field of view 
producing static fields causing image distortion. 
 
Table 1. Terminology 
Older  
MR Safe 
 
When used in the MR environment presents no 
additional risk to the patient or other individual but may 
affect the quality of the image obtained. The MR 
conditions in which the device was tested should be 
specified in conjuction with the term “MR Safe” because 
it may not be safe under other MR conditions.   
MR 
Compatible 
MR safe and when used under MR field does not affect 
image quality or its functioning properties. Again the 
MR conditions must be specified. 
Newer  
MR Safe Item with no known hazards in any MR field. 
Nonconducting, nonmetallic, nonmagnetic.  
MR 
Conditional 
Item with no known hazards in a specific MR environment 
and conditions of use eg. static field strength, spatial 
magnetic gradient, dB/dt (time varying magnetic fields), 
RF fields and SAR. Additional conditions specifying 
configuration of the item may be required. 
MR Unsafe Item with known hazards in all MR environments. 
 
Studies covering the consequences of MRI in 
pacemakers and defibrillators 
 
Several ex vivo and animal studies concerning 
pacemaker and ICD interactions with magnetic fields of 
MR examination have been set off by advances in device 
technology. Devices in use today pose greater resistance 
to changes in function while in MRI conditions 4 and 
measurements of lead temperature in vivo demonstrated 
no considerable alterations in stimulation thresholds or 
heat related lesions. 2-4 Recent reports 2,5,7 demonstrate a 
relative safety during MRI examination for newer devices 
under 0.5-3.0 Tesla magnetic field exposure and only few 
and minor alterations in threshold values or cases 
requiring reprogramming of the device or battery 
depletion.  
 
In vitro and animal subjects 
 
Pavlicek et al in 1983 showed that RF energy fields 
could inhibit demand pacemakers and that gradient 
magnetic fields could produce currents mimicking cardiac 
electrical activity with a 17 Gauss threshold to 
asynchronous mode initiation. Fetter et al in 1984 
postulated that under 0.15T magnetic field a reversion 
from demand to asynchronous mode happened without 
reed switch sticking or magnetizing or damage to other 
components of the electrical circuit. Erlebacher et al in 
1986 showed total inhibition of atrial and ventricular 
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output or rapid atrial pacing of various DDD pacemakers 
under 0.5T field due to RF interference. Lauck et al in 
1995 tested the behavior of VVI, VVIR, VOO, DDD, 
DDDR, DOO modes under 0.5T and observed a 
reversible reed switch activation with asynchronous 
stimulation in all pacemakers. Devices with auto mode 
switch to demand pacing or programmed reed switch 
inactivation were triggered in dual chamber and inhibited 
in single chamber mode while devices in asynchronous 
mode showed no conflicts concerning rate and capture 
during MRI. Thus, they suggested turning into 
asynchronous mode before 0.5T MRI or device 
inactivation in non pacemaker depended patients. Hayes 
et al in 1987 investigated in vivo various single and dual 
chamber devices under 1.5T MR scanners. Except 
reversion to asynchronous mode and reed switch 
activation, RF signal exposure caused rapid pacing at a 
cycle length of 200ms (the frequency of RF emition) 
resulting in blood pressure precipitation as a result of an 
“antenna” effect of the device output circuits on 7 of the 8 
investigated pulse generators. Achenbach et al in 1997 
showed that no interference was observed in 
asynchronous mode either VOO or DOO, while VVI and 
DDD devices posed inhibition and rapid pacing during 
spin echo imaging due to above sensing threshold in atrial 
leads currents that triggered ventricular response. Lead 
heat is of great importance in MR environment and 
technically difficult to measure a fact coupled with results 
fluctuation. Achenbach et al in the same study used an 
optical temperature sensor to record pacing lead tip 
temperature. A 63.10C maximal temperature increase 
after 90 sec of scanning was observed while in 7 
electrodes the temperature increase exceeded 150C. 
Sommer et al in 2000 connected specific absorption rate 
(SAR) with the maximum temperature increase that was 
8.90C at 0.6 W/Kg and 23.50C at 1.3W/Kg. Roguin et al 
in2004 report a maximal heating of 70C under 3.7 W/Kg 
SAR, while in vivo in the same study there was no 
significant rise of the temperature when leads were into 
the right ventricle of a canine model due to heat diffusion 
through blood. In addition 15 dogs with ICD leads were 
scanned under prolonged and high SAR protocols (3-
4W/Kg / 3-4 hours) and no heat induced injury was 
observed. Schmiedel et al in 2005 also reported no heat 
induced tissue damage. Luechinger et al in 2005 stated 
that cell damage during lead implantation cannot be 
distinguished from that of heat and in vivo only minor 
changes in stimulation thresholds (<0.5V), while no heat 
induced damage were observed despite the increasing 
temperature up to 200C, using leads with additional 
thermocouple wires as temperature sensors. Roguin et al 
one year earlier used optic fibre measurements and no 
heat rise was observed but they also found no significant 
heat damage or threshold changes. Of course both studies 
took place under in vivo blood flow cooling environment 
of animal hearts. Force and torque in vivo and in vitro 
was minimal in a series of studies 27,28,30 with no tissue 
damage, no permanent lose of capture and no function 
problems concerning newer devices. 
 
Human studies 
 
Most studies until late 1990s (Table 2) reveal no lethal 
consequences on pacemaker patients underwent MRI. 
Only few reports of unexpected deaths were posted. 13-15 
Vahlahaus et al in 2001 used a 0.5 T MR system on 32 
pacemaker patients combining this with a just after and 3 
months later PM interrogation. Decreased battery voltage 
was observed immediately after MRI which recovered 3 
months later. Lead impedance, sense and thresholds were 
not affected. Reed switch activation by static field was 
not predictable. Martin et al in 2004 tested 54 non 
pacemaker depended patients at 1.5 T MRI. Statistically 
significant threshold changes were up to 9.4% but 
patients’ symptoms were mild and ECG changes did not 
pose a threat to stop the examination. Schmiedel et al in 
2005 tested (brain MRI) 45 pacemeker patients (63 
MRIs) at 1.5 T of a maximum SAR of 1.2 W/Kg and 
under continuous ECG and oximetry monitoring. Devices 
were reprogrammed to asynchronous mode prior to the 
examination. An increase <2.980C max to the temperature 
observed is not of great concern. No changes concerning 
programmed parameters or damage of device (in vitro 
n=0/24) and in vivo n=0/63) and no significant (<1V) 
changes of thresholds immediately after MR or in 3 
months follow up were observed. Sommer et al tested 82 
patients with Medtronic pacemaker devices implanted 
under 1.5 T MR (pacemaker depended patients and those 
required thorax MRI were excluded). SAR was at 
1.5W/Kg. Parameters investigated were troponin I levels 
and PM function (capture threshold before and three 
months after). Reprogramming to asynchronous mode of 
patients with heart rates <60 bpm and sense only mode to 
those with heart rates >60 bpm was used to avoid MR 
induced inhibition and arrhythmias respectively. Capture 
threshold increased (p=0.017) and so did troponin I 
levels. In 2 of 195 leads capture threshold increased at 
1V/ 0.4 ms and in one case this was followed by an 
increase of troponin I levels from 0.02 baseline to 0.16 
post MR. Nazarian et al in 2006 investigated 55 patients 
with clinical need of MR examination having devices (31 
PM/24 ICD) that have been tested by in vitro phantom 
and in vivo animal testing and shown to be MRI safe. 27 
They posted that MRI examination (cardiac and non 
cardiac) in patients with selected devices can be safe if all 
technical aspects and precautions are under consideration. 
Asynchronous mode for PM dependent patients and 
demand for the rest has been selected while magnet 
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response and tachyarrhythmia function were set to off. 
No considerable changes in lead impedances, capture 
thresholds, sensing amplitudes were observed in a median 
99 days follow up and no abnormal activation or 
inhibition of pacing were observed during MRIs while 
diagnosis have been set in 100% of non thoracic and in 
93% of thoracic studies. Gimbel et al in 2005 tested 10 
PM depended patients under MRIs of neck and head of a 
whole body SAR < 2 W/Kg end reprogrammed devices to 
VOO or DOO 60 ppm. No arrhythmias or other events 
were noted during or post MRI and no battery depletion 
observed. Thresholds post MRI and 3 months later had no 
significant changes. Nazarian et al and Goldsher et al 
in2006 posted similar results on PM dependent patients. 
To draw a conclusion of these studies, PM dependent 
patients may undergo MRI safely if special parameters 
are arranged including reprogramming of the device, use 
of MR sequences with low magnetic field power, careful 
monitoring and use of transmit-receive coil in cranial 
scans. 
With regard to ICDs, laboratory testing seems to pose 
that modern systems can undergo MR scanning without 
harm vs older systems that were irreversibly damaged (4). 
Naehle et al in 2009 tested 18 ICD non pacemaker 
dependent patients under MRI conditions concerning all 
body parts examinations. No thermal injury or significant 
changes in pacing parameters was observed. All devices 
could be interrogated normally post MRI while no torque 
or heat sensations were reported by the patients during 
the examination. Mean battery voltage had dipped from 
pre MRI 3.86 ± 1.48 V, to post MRI 3.83 ± 1.48 V with 
reversion to 3.9 ± 1.52 at follow up. Gimbel et al in 2005 
(10) tested 7 ICD patients underwent 8 MRI scans at 1.5 
T and no adverse effects clinical or electrical were 
reported. Nazarian et al in 2006 (7) on the largest MR 
scanned ICD patients reported series posed no issues in 
all 24 patients and devices. Roguin et al in 2008 showed 
similar results (2). However, careful evaluation of all 
physical/technical and clinical/patient aspects must be 
performed before any MR scanning to avoid adverse 
effects. 
 
Technical aspects and clinical safety concerns in MRI 
of patients with implanted devices 
 
Given the wide range of available MRI systems and 
conditions, pacemakers, ICDs, leads and a variety of 
diseases with MRI indication it is difficult to post specific 
recommendations for routine use. None MR scanning 
should be considered safe despite the several studies 
posing the opposite. Today’s devices seem to be more 
safe but they are neither MR safe nor MR conditional 
labeled. However, Medtronic developed and tested 
EnRhyhm-MRI SureScan pacing system to be used safely 
under MRI conditions (8). Anyway, indications have to 
be carefully evaluated and the risks should be discussed 
with the patient and informed consent must be obtained. 
The whole examination must be done under strict 
observation by MR and electrophysiology expert 
personel. Monitoring and full resuscitation facilities must 
be present and both thoughtful pre-MR reprogramming 
and thorough follow up must be performed. As posted by 
Roguin et al in 2008 position paper three groups of 
patients with risk correspondence are recognized and 
related recommendations were given (Table 3).   
 
Conclusion 
 
Although MRI has become an increasingly attractive 
imaging modality over the past decades many caveats and 
contraindications were posted regarding MR scans in 
patients with implanted devices. Despite the considerable 
number of studies and the amount of patients with 
implanted devices underwent MR scan safely, special 
safety issues must always be considered regarding 
heating, arrhythmogenesis, and device function that 
demand measures to mitigate them related to both the 
device and the MR scanner. MRI may be done after 
thorough evaluation of the indication and in the absence 
of an alternative imaging modality. In any case informed 
consent must be obtained after discussing the risks with 
the patient. Pre-reprogramming the device, patient 
monitoring during MR and thorough follow up must 
always be performed. New devices MR-conditional 
labeled are under investigation  and others will be 
developed in the future paving the way to safe MRI scans 
in the growing population of patients who benefit from 
implanted pacemakers and defibrillators.   
 
Table 3. MRI and pacemakers: safety concerns & guidelines. 
(1) Pacemaker‐
dependent 
patients (very 
high risk) 
If  underlying  rhythm  is  too  slow—
reconsider  indication.  The  threshold  for 
imaging and  the safety  requirements are 
higher, but no absolute contraindication 
(2) ICD patient 
(non‐dependent)a 
(high risk) 
The patient must have a documented  
extremely serious, life threatening or 
severely quality‐of‐life limiting condition 
(3) Pacemaker 
patient (non‐
dependent) 
(low risk) 
The  patient  must  have  a  documented 
very  serious,  life  threatening  or  severely 
quality‐of‐life limiting condition. 
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Table 2.  Published reports (1989–1998) describing the non‐lethal consequences of magnetic resonance imaging in  
pacemaker patients 
 
Author Indication for MR 
imaging 
Pacemaker 
model 
Dual‐/single‐
chamber 
Lead 
polarity 
PM 
mode 
Field 
strength (T) 
Outcome after MR 
imaging 
Alagona (1989) Brain tumor AFP Dual Unipolar OOO 1.5 Normal 
Inbar (1993) Cerbellopontine 
syndrome 
Paragon II Dual Bipolar OOO 1.5 Normal 
Gimbel (1996) Heart valve AFP Single Unipolar OOO 1.5 Image artifact 
 Brain tumor Genesis Dual Unipolar DOO 0.5 Pause (2s) 
 CIA Paragon II Dual Bipolar OOO 0.35 Normal 
 Pituitary tumor  Synchrony Dual Bipolar DOO 1.5 Normal 
 Cervical disc Synchrony II Dual Bipolar DDD 1.0 Normal 
Fontaine (1998) Dizziness Thera DR Dual Bipolar VVI 1.5 Rapid vent pacing 
Garcia Bolao (1998) Cranial nerve palsy Meta Dual Bipolar AOO  1.0 Asynchronous pacing 
Sommer (1998)  CNS Elite Dual NA DOO 0.5 Asynchronous pacing 
 Cardiac tumor Elite Dual NA DOO 0.5 Asynchronous pacing 
 Periprosthetic 
(asc.aorta) 
Elite Dual NA DOO 0.5 Asynchronous pacing 
 Pseudoaneurysm Relay Dual NA VOO 0.5 Normal 
 Paravalvar Prosth Vista Dual NA DDD 0.5 Asynchronous pacing 
 Constrictive 
pericarditis 
Dialog Single NA VVI 0.5 Asynchronous pacing 
CIA = ; CNS = ; NA = not available; PM = pacemaker 
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